Payment overview · 2025
General Payments
$318.72
18 reported records · 9 companies
Healthcare provider profile · identity verified
Thimmiah Ramesh, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · WYANDOTTE, MI · NPI 1912934340
Verified facts
What the public records show
CMS Open Payments records show Thimmiah Ramesh, M.D received $318.72 in general payments during 2025 across 18 reported records.
GlaxoSmithKline, LLC. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.17 | 24.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.78 | 21.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.27 | 18.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.61 | 7.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.75 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.72 | 6.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.40 | 5.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.97 | 5.0% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $15.05 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $318.72 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.17 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.78 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.27 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.65 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 168 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
168 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1418 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 581 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 131 |
| Gabapentin | Gabapentin | 364 | 61 |
| Lisinopril | Lisinopril | 330 | 87 |
| Metformin Hcl | Metformin Hcl | 325 | 94 |
| Omeprazole | Omeprazole | 322 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 315 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 68 |
| Ibuprofen | Ibuprofen | 251 | 84 |
| Alprazolam | Alprazolam | 224 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 67 |
| Simvastatin | Simvastatin | 214 | 51 |
| Potassium Chloride | Potassium Chloride | 212 | 67 |
| Losartan Potassium | Losartan Potassium | 202 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 49 |
| Furosemide | Furosemide | 185 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 58 |
| Azithromycin | Azithromycin | 169 | 122 |
| Ozempic | Semaglutide | 168 | 17 |
| Trazodone Hcl | Trazodone Hcl | 160 | 27 |
| Diazepam | Diazepam | 158 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 153 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 144 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 25 |
| Pregabalin | Pregabalin | 119 | 24 |
| Eliquis | Apixaban | 113 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 112 | 51 |
| Prednisone | Prednisone | 108 | 64 |
| Ventolin Hfa | Albuterol Sulfate | 108 | 46 |
| Famotidine | Famotidine | 103 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 29 |
| Trulicity | Dulaglutide | 95 | 17 |
| Lorazepam | Lorazepam | 92 | 19 |
| Allopurinol | Allopurinol | 91 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 59 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 21 |
| Mounjaro | Tirzepatide | 77 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 69 | 16 |
| Meloxicam | Meloxicam | 68 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 53 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 43 |
| Nystatin | Nystatin | 63 | 24 |
| Atenolol | Atenolol | 62 | 16 |
| Warfarin Sodium | Warfarin Sodium | 61 | 11 |
| Carvedilol | Carvedilol | 60 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 17 |
| Sertraline Hcl | Sertraline Hcl | 59 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 55 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 55 | 18 |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Acyclovir | Acyclovir | 52 | 21 |
| Methylprednisolone | Methylprednisolone | 52 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 17 |
| Hydrocortisone | Hydrocortisone | 49 | 16 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Naproxen | Naproxen | 45 | 25 |
| Levetiracetam | Levetiracetam | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 15 |
| Jardiance | Empagliflozin | 41 | 13 |
| Phenobarbital | Phenobarbital | 41 | suppressed |
| Colchicine | Colchicine | 40 | 15 |
| Glimepiride | Glimepiride | 40 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 27 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 28 |
| Promethazine Hcl | Promethazine Hcl | 37 | 14 |
| Spironolactone | Spironolactone | 37 | 12 |
| Sucralfate | Sucralfate | 36 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 30 |
| Chlorthalidone | Chlorthalidone | 31 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 30 | 14 |
| Glipizide | Glipizide | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 13 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ibu | Ibuprofen | 23 | 17 |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | 11 |
| Baclofen | Baclofen | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 12 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $318.72 · 18 records | GlaxoSmithKline, LLC. | BREZTRI, Cologuard Collection Kit, MOUNJARO, Ozempic, PAXLOVID, TRELEGY ELLIPTA, VOQUEZNA, YUPELRI, ZEPBOUND, Zubsolv | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error